Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | ||
Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Lancora | Ivabradine | Heart failure, NYHA class II or III | Reimburse with clinical criteria and/or conditions | Complete | ||
Kyprolis (with lenalidomide) | Carfilzomib (with lenalidomide) | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete |